How we diagnose and treat iron deficiency anemia

American Journal of Hematology

Volumn 91, Issue 1, 2016, Pages 31-38

  Auerbach, Michael ^a,b   Adamson, John W ^c  

^a GEORGETOWN UNIVERSITY   (United States)

^b University of California San Diego ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; FERRITIN; FERROUS SULFATE; IRON DEXTRAN; METHYLPREDNISOLONE; TRANSFERRIN RECEPTOR; ANTIANEMIC AGENT; FERROUS ION; MAGNETITE;

ADULT; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CHEILOSIS; CONTROLLED CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES BLEEDING; EXHAUSTION; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GROWTH DISORDER; HUMAN; INSOMNIA; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; LEARNING DISORDER; LEG CRAMP; MALE; MENORRHAGIA; METRORRHAGIA; MIDDLE AGED; NOCTURNAL LEG CRAMP; PALLOR; PATIENT COMPLIANCE; PICA; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RETICULOCYTE HEMOGLOBIN CONTENT; SOMNOLENCE; TONGUE DISEASE; UNSPECIFIED SIDE EFFECT; ANEMIA, IRON-DEFICIENCY; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; FERRITINS; FERROSOFERRIC OXIDE; FERROUS COMPOUNDS; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX;

EID: 84954382435     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24201     Document Type: Article

References (66)

1. World Health Organization/UNICEF/UNU. Iron Deficiency Anaemia: Assessment, Prevention, and Control. A guide for Programme Managers. Geneva, Switzerland: World Health Organization; 2001.
2. Kassebaum N, Rashmi J, Naghavi M, et al. A systemic analysis of global anemia burden from 1990 to 2010. Blood 2014;123:615-624.
3. Gulmez H, Akin Y, Savas M, et al. Impact of iron supplementation on sexual dysfunction of women with iron deficiency anemia in short term: A preliminary study. J Sex Med 2014;4:1042-1046.
4. McClung J, Murray-Kolb L. Iron nutrition and premenopausal women: Effects of poor iron status on physical and neuropsychological performance. Annu Rev Nutr 2013;33:271-288.
5. Stoltzfus R. Iron deficiency: Global prevalence and consequences. Food Nutr Bull 2003;24:S99-S103.
6. Haas J, Brownlie T. Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship. J Nutr 2001;131:676S-688S.
7. Congdon E, Westerlunjd B, Algarin C, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr 2012;160:1227-1233.
8. Pasricha S, Dreskesmith H, Black J, et al. Control of iron deficiency in low- and middle-income countries. Blood 2013;121:2607-2617.
9. Simpson E, Longley M, East J. Pica during pregnancy in low-income women born in Mexico. West J Med 2000;173:20-24.
10. Kettaneh A, Eclache V, Sontaq C, et al. Pica and food craving in patients with iron-deficiency anemia: A case-control study in France. Am J Med 2005;118:185-188.
11. Trost L, Bergfeld W, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006;54:824-844.
12. Silber M, Becker P, Earley C, et al. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc 2013;88:977-986.
13. Howell J, Monto R. Syndrome of anemia, dysphagia and glossitis (Plummer Vinson syndrome). N Engl J Med 1953;249:1009-1012.
14. Crosby W. Whatever became of chlorosis? Jama 1987;257:2799-2800.
15. Hillman S, Finch C. Red Cell Manual. Transfusion, 5th ed. John Wiley and Sons. pp 1537-2995.
16. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-1057.
17. Cook J, Flowers C, Skikne B. The quantitative assessment of body iron. Blood 2003;101:3359-3364.
18. Stockman R. The treatment of chlorosis with iron and some other drugs. Br Med J 1893;1:881-885.
19. Blaud P. Sur les maladies chloropiques et sur un mode de traitement specifique dons ces affecions. Rev Med Fr Etrant 1832;45:357-367.
20. Kruske S, Ruben A, Brewster D. An iron treatment trial in an aboriginal community: Improving non-adherence. J Paediatr Child Health 1999;35:153-158.
21. Tolkien Z, Stecher L, Mander A, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. Plos One 2015;10:e0117383. DOI:10.1371/journal.pone.0117383.
22. Beard J. Effectiveness and strategies of iron supplementation during pregnancy. Am J Clin Nutr 2000;71:1288S-1294S.
23. Makrides M, Crowther C, Gibson R, et al. Efficacy and tolerability of low-dose iron supplements during pregnancy: A randomized controlled trial. Am J Clin Nutr 2003;78:145-153.
24. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn's disease. A randomized, controlled trial. Ann Intern Med 1997;126:782-787.
25. Kulnigg S, Gasche C. Systematic review: Managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006;24:1507-1523.
26. Bothwell T, Pirzio-Biroli G, Finch C. Iron absorption. I. Factors influencing absorption. J Lab Clin Med 1958;51:24-36.
27. Auerbach M, Ballard H, Glaspy J. Clinical Update: Intravenous iron for anaemia. Lancet 2007;369:1502-1504.
28. Auerbach M, Coyne D, Ballard H. Intravenous iron: From anathema to standard of care. Am J Hematol 2008;83:580-588.
29. Danielson B. Structure, chemistry and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15:S93-S98.
30. Goetsch A, Moore C, Minnich V. Observations on the effects of massive doses of iron given intravenously to patients with hypochromic anemia. Blood 1946;1:129-142.
31. Nissim J. Intravenous administration of iron. Lancet 1947;1:49-51.
32. Baird I, Podmore D. Intra-muscular iron therapy in iron deficiency anemia. Lancet 1954;2:942-946.
33. Kanakaraddi V, Hoskatti C, Nadig V, et al. Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia. J Assoc Phys India 1973;21:849-853.
34. Varde K. Treatment of 300 cases of iron deficiency of pregnancy by total dose infusion of iron-dextran complex. J Obstet Gynaecol Br Comm 1964;71:919-922.
35. Marchasin S, Wallerstein R. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 1964;23:354-358.
36. Hamstra R, Block M, Schocket A. Intravenous iron dextran in clinical medicine. Jama 1980;243:1726-1731.
37. Eschbach J, Egrie J, Downing M, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78.
38. Chandler G, Harchowal J, Macdougall I. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001;38:988-991.
39. Auerbach M, Ballard H. Clinical use of intravenous iron: Administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010;2010:338-347.
40. Michael B, Coyne D, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61:1830-1839.
41. Auerbach M, Pappadakis J, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011;86:860-862.
42. Auerbach M, Strauss W, Auerbach S, et al. Safety and efficacy of total dose infusion of 1020 mg ferumoxytol administered over 15 minutes. Am J Hematol 2013;88:944-947.
43. Chertow G, Mason P, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382.
44. Chritchley J, Dunbar Y. Adverse events associated with intravenous iron infusion (low -molecular weight iron dextran and iron sucrose): A systematic review. Transfus Altern Transfus Med 2007;9:8-36.
45. Moniem K, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med 2007;9:37-42.
46. Sav T, Tokgoz B, Sipahioglu M, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007;29:423-426.
47. Macdougall I, Strauss W, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014;4:705-712.
48. Hetzel D, Strauss W, Bernard K, et al. A phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol 2014;89:646-650.
49. Okam M, Mandell E, Hevelone N, et al. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol 2012;87:E123-E124.
50. Wysoski D, Swartz L, Borders-Hemphill V, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010;85:650-654.
51. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc 2015;90:12-23.
52. Barton J, Barton E, Bertoli L, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000;109:27-32.
53. Fishbane S, Ungureanu V, Maesaka J, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534.
54. Bircher A, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014;34:707-723.
55. Auerbach M, Chaudhry M, Goldman H, et al. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial. J Lab Clin Med 1998;131:257-260.
56. Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988;111:566-570.
57. Kshirsager A, Freburger K, Ellis A, et al. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med 2013;126:541.
58. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998;31:81-86.
59. Jahn M, Andreasen H, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011;78:480-491.
60. Myers B, Myers A, Moore J. Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy. Obstet Med 2012;5:105-107.
61. Christoph P, Schuller C, Studer H, et al. Intravenous iron treatment in pregnancy: Comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med 2012;40:469-474.
62. Kalra P, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant, in press.
63. Reinisch W, Staun M, Tandon R, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1, 000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013;108:1877-1888.
64. Birgegard G, Henry D, Thomsen L, et al. Intravenous iron isomaltoside 1000 (Monofer) as mono therapy in comparison with oral iron sulphate in patients with non-myeloid malignancies associatged with chemotherapy induced anemia (CIA). In: Published Abstract, Presented at Annual Meeting of Multinational Association of Supportive Care in Cancer. Copenhagen, Denmark; 2015.
65. Johansson P, Rasmussen A, Thomsen L. Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: A rondomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang, in press.
66. Favrot B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued iron-deficient women - PREFER a randomized placebo-controlled study. PLoS One 2014;9:e94217. doi:10.1371/journal.pone0094217.